Literature DB >> 23089339

Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy.

Erik D Hanson1, Andrew K Sheaff, Suchi Sood, Lei Ma, Jack D Francis, Andrew P Goldberg, Ben F Hurley.   

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with weakness, fatigue, sarcopenia, and reduced quality of life (QoL). Black men have a higher incidence and mortality from PCa than Caucasians. We hypothesized that despite ADT, strength training (ST) would increase muscle power and size, thereby improving body composition, physical function, fatigue levels, and QoL in older black men with PCa.
METHODS: Muscle mass, power, strength, endurance, physical function, fatigue perception, and QoL were measured in 17 black men with PCa on ADT before and after 12 weeks of ST. Within-group differences were determined using t tests and regression models.
RESULTS: ST significantly increased total body muscle mass (2.7%), thigh muscle volume (6.4%), power (17%), and strength (28%). There were significant increases in functional performance (20%), muscle endurance (110%), and QoL scores (7%) and decreases in fatigue perception (38%). Improved muscle function was associated with higher functional performance (R (2) = 0.54) and lower fatigue perception (R (2) = 0.37), and both were associated with improved QoL (R (2) = 0.45), whereas fatigue perception tended to be associated with muscle endurance (R (2) = 0.37).
CONCLUSIONS: ST elicits muscle hypertrophy even in the absence of testosterone and is effective in counteracting the adverse functional consequences of ADT in older black men with PCa. These improvements are associated with reduced fatigue perception, enhanced physical performance, and improved QoL. Thus, ST may be a safe and well-tolerated therapy to prevent the loss of muscle mass, strength, and power commonly observed during ADT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089339      PMCID: PMC3593619          DOI: 10.1093/gerona/gls206

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  38 in total

1.  Androgen receptor protein expression in prostatic tissues in Black and Caucasian men.

Authors:  E Oluwabunmi Olapade-Olaopa; Charles A Muronda; E Hugh MacKay; Alex P Danso; Davinder P Sandhu; Timothy R Terry; Fouad K Habib
Journal:  Prostate       Date:  2004-06-01       Impact factor: 4.104

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 3.  The role of androgens and estrogens on healthy aging and longevity.

Authors:  Astrid M Horstman; E Lichar Dillon; Randall J Urban; Melinda Sheffield-Moore
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-26       Impact factor: 6.053

4.  The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.

Authors:  Shehzad Basaria; Lauren Collins; E Lichar Dillon; Katie Orwoll; Thomas W Storer; Renee Miciek; Jagadish Ulloor; Anqi Zhang; Richard Eder; Heather Zientek; Gilad Gordon; Syed Kazmi; Melinda Sheffield-Moore; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-28       Impact factor: 6.053

5.  Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer.

Authors:  Angela S Alberga; Roanne J Segal; Robert D Reid; Chris G Scott; Ronald J Sigal; Farah Khandwala; James Jaffey; George A Wells; Glen P Kenny
Journal:  Support Care Cancer       Date:  2011-05-03       Impact factor: 3.603

6.  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.

Authors:  Pamela A Hansen; Christopher B Dechet; Christina A Porucznik; Paul C LaStayo
Journal:  PM R       Date:  2009-11       Impact factor: 2.298

8.  A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations.

Authors:  Norman A Mazer
Journal:  Steroids       Date:  2009-02-07       Impact factor: 2.668

9.  Racial differences in prostate androgen levels in men with clinically localized prostate cancer.

Authors:  James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Physical function in men with prostate cancer on androgen deprivation therapy.

Authors:  Cheryl A Clay; Subashan Perera; Julie M Wagner; Megan E Miller; Joel B Nelson; Susan L Greenspan
Journal:  Phys Ther       Date:  2007-08-07
View more
  29 in total

Review 1.  The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.

Authors:  T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

2.  Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.

Authors:  Chunliu Pan; Neha Jaiswal Agrawal; Yanni Zulia; Shalini Singh; Kai Sha; James L Mohler; Kevin H Eng; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  JCI Insight       Date:  2020-03-26

3.  A randomized controlled exercise training trial on insulin sensitivity in African American men: The ARTIIS study: Major category: study design, statistical design, study protocols.

Authors:  Robert L Newton; William D Johnson; Chelsea Hendrick; Melissa Harris; Emanuel Andrews; Neil Johannsen; Ruben Q Rodarte; Daniel S Hsia; Timothy S Church
Journal:  Contemp Clin Trials       Date:  2015-05-12       Impact factor: 2.226

4.  Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial.

Authors:  M K Norris; G J Bell; S North; K S Courneya
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-16       Impact factor: 5.554

Review 5.  The molecular basis for load-induced skeletal muscle hypertrophy.

Authors:  George R Marcotte; Daniel W D West; Keith Baar
Journal:  Calcif Tissue Int       Date:  2014-10-31       Impact factor: 4.333

6.  TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.

Authors:  Chunliu Pan; Shalini Singh; Deepak M Sahasrabudhe; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  Endocrinology       Date:  2016-09-09       Impact factor: 4.736

Review 7.  The Independent Effects of Strength Training in Cancer Survivors: a Systematic Review.

Authors:  Erik D Hanson; Chad W Wagoner; Travis Anderson; Claudio L Battaglini
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

Review 8.  The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Authors:  Peter Busch Østergren; Caroline Kistorp; Finn Noe Bennedbæk; Jens Faber; Jens Sønksen; Mikkel Fode
Journal:  Nat Rev Urol       Date:  2016-04-26       Impact factor: 14.432

9.  Castration induces satellite cell activation that contributes to skeletal muscle maintenance.

Authors:  Alanna Klose; Wenxuan Liu; Nicole D Paris; Sophie Forman; John J Krolewski; Kent L Nastiuk; Joe V Chakkalakal
Journal:  JCSM Rapid Commun       Date:  2018

10.  Effects of Resistance Training on Arterial Stiffness in Persons at Risk for Cardiovascular Disease: A Meta-analysis.

Authors:  William Evans; Quentin Willey; Erik D Hanson; Lee Stoner
Journal:  Sports Med       Date:  2018-12       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.